BBHC
NAVB

Brown Brothers Harriman & Co’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Brown Brothers Harriman & Co’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-50
Closed -$2K – 832
2013
Q4 		$2K Hold
50
– – ﹤0.01% 632
2013
Q3 		$3K Hold
50
– – ﹤0.01% 642
2013
Q2 		$3K Buy
+50
New +$2.5K ﹤0.01% 690

Other funds holding NAVB

PM
Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Brown Brothers Harriman & Co's NAVB Position: Q1 2014 in Review

Brown Brothers Harriman & Co sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q1 2014, closing a stake of 50 shares — an estimated $2K sold.

Brown Brothers Harriman & Co first reported a position in NAVB in Q2 2013 and held it in 3 quarters. The position peaked at $3K in Q3 2013. 83 funds tracked by Wall St. Rank hold NAVB as of Q1 2014.

  • Brown Brothers Harriman & Co reported no remaining Navidea Biopharmaceuticals Inc. position as of Q1 2014 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 50 Navidea Biopharmaceuticals Inc. shares in Q1 2014, an estimated $2K.
  • Brown Brothers Harriman & Co first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 3 quarters.
  • Brown Brothers Harriman & Co's Navidea Biopharmaceuticals Inc. position peaked at $3K in Q3 2013.
  • 83 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q1 2014.

Based on Brown Brothers Harriman & Co's 13F filing for Q1 2014, filed 15 May 2014.